Britain to account prostate cancer tablet in U-turn

<p>LONDON (Reuters) – <span>Britain</span>‘s drug watchdog has topsy-turvy a argumentative preference not to account a new <span>prostate cancer</span> tablet that was grown in a nation after builder <span>Johnson Johnson</span> concluded a new bonus on reserve to a <span>UK state medical service</span>.</p>
<p> Zytiga, that is famous chemically as abiraterone, was authorized final year in Europe and a United States to provide modernized prostate cancer in patients who formerly perceived chemotherapy.</p>
<p> The drug was grown by researchers during a <span>Institute of Cancer Research</span> and London’s Royal Marsden Hospital. British curative organisation BTG is entitled to accept kingship payments on a drug.</p>
<p> The rejecting of a drug in Feb in <span>draft guidance</span> from Britain’s <span>National Institute for Heal...